Loading clinical trials...
Loading clinical trials...
A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer
Conditions
Interventions
BET Bromodomain Inhibitor ZEN-3694
Biopsy Procedure
+5 more
Locations
6
United States
Boston Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
NYU Langone Hospital - Long Island
Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, United States
Start Date
May 18, 2023
Primary Completion Date
March 31, 2027
Completion Date
March 31, 2027
Last Updated
April 13, 2026
NCT06492759
NCT06500455
NCT03723928
NCT04704661
NCT05673200
NCT04550494
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions